I don't think anything's really changed since Wednesday or Thursday of last week, but the market is moving in that general downward direction. Yeah, I mean, their earnings was kind of a non-event in many respects. There was a lot of left in that kind of TBD category.We still really don't know what's going to happen with China when that revenue is going to come back, How much of it is going to come back. But we believe that probably will be some China revenue. So that was a kind of a mixed message.We know th ...

Yes, Melissa, thank you very much. And Rob, it's great to see you. I gotta say, I was surprised on the call not to hear more superlatives about the amazing results in Singapore because as far as I can do, I I did some quick research.There has never been a a hotel casino property anywhere in the world in any quarter that achieved what you did. $768 million. No, no, no.I just It's a It's a big deal. >> It's You're absolutely correct. I've been doing this 40 years.No building anywhere industry came close to th ...

Group 1: Goldman Sachs - Goldman Sachs' shares have outperformed the Zacks Financial - Investment Bank industry over the past year, with a growth of +72.7% compared to +42.6% for the industry [5] - The company's restructuring initiatives are expected to enhance its presence in overseas markets, supported by decent cash levels and a solid credit profile [5][6] - Despite strong earnings performance, the global banking and markets division may face pressure due to capital market volatility and geopolitical concerns [6] Group 2: Progressive Corp. - Progressive's shares have outperformed the Zacks Insurance - Property and Casualty industry over the past year, with a growth of +41.3% compared to +18% for the industry [7] - The company is benefiting from higher premiums and a strong product portfolio, focusing on becoming a one-stop insurance destination [7][8] - However, exposure to catastrophe losses and escalating expenses pose challenges to its margins [9] Group 3: Boston Scientific - Boston Scientific's shares have outperformed the Zacks Medical - Products industry over the past year, with a growth of +60.2% compared to +13.9% for the industry [10] - The company is experiencing strong demand across its MedSurg and Cardiovascular lines, with positive contributions from acquisitions [10][11] - Despite macroeconomic concerns, the company expects strong organic growth in 2025, although rising costs and foreign exchange headwinds are significant risks [12] Group 4: Cooper-Standard Holdings Inc. - Cooper-Standard's shares have declined -3.9% over the past year, while the Zacks Automotive - Original Equipment industry has seen a decline of -9.2% [13] - The company achieved a 96.8% year-over-year increase in adjusted EBITDA to $54.3 million, driven by cost optimizations [13] - However, high debt levels and rising interest costs present risks, alongside challenges from weak global auto production and pricing pressures [15]